1368488
2017
1
heidelberg-university-faculty-of-medicine
50
creator
asc
year
1
196
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22WWL5HK8F%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Allerberger%20et%20al.%22%2C%22parsedDate%22%3A%222017-03-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAllerberger%2C%20F.%2C%20Cambau%2C%20E.%20and%20Lange%2C%20C.%20%282017%29.%20%3Cb%3EJoint%20efforts%20urgently%20needed%20at%20times%20of%20emerging%20tuberculosis%20drug%20resistance%3C%5C%2Fb%3E.%20Clinical%20Microbiology%20and%20Infection%20%3Ci%3E23%3C%5C%2Fi%3E%2C%20129%26%23x2013%3B130%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2016.08.023%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2016.08.023%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Joint%20efforts%20urgently%20needed%20at%20times%20of%20emerging%20tuberculosis%20drug%20resistance%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Allerberger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Lange%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-03-01%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2016.08.023%22%2C%22ISSN%22%3A%221198-743X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.clinicalmicrobiologyandinfection.com%5C%2Farticle%5C%2FS1198-743X%2816%2930362-7%5C%2Ffulltext%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-12T09%3A40%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22W49YLEFB%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Andre%20et%20al.%22%2C%22parsedDate%22%3A%222017-03-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAndre%2C%20E.%2C%20Goeminne%2C%20L.%2C%20Cabibbe%2C%20A.%2C%20Beckert%2C%20P.%2C%20Mukadi%2C%20B.%20K.%2C%20Mathys%2C%20V.%2C%20Gagneux%2C%20S.%2C%20Niemann%2C%20S.%2C%20Ingen%2C%20J.%20V.%20and%20Cambau%2C%20E.%20%282017%29.%20%3Cb%3EConsensus%20numbering%20system%20for%20the%20rifampicin%20resistance-associated%20rpoB%20gene%20mutations%20in%20pathogenic%20mycobacteria%3C%5C%2Fb%3E.%20Clinical%20Microbiology%20and%20Infection%20%3Ci%3E23%3C%5C%2Fi%3E%2C%20167%26%23x2013%3B172%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2016.09.006%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2016.09.006%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Consensus%20numbering%20system%20for%20the%20rifampicin%20resistance-associated%20rpoB%20gene%20mutations%20in%20pathogenic%20mycobacteria%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Andre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Goeminne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Cabibbe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Beckert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20Kabamba%22%2C%22lastName%22%3A%22Mukadi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Mathys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Gagneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Niemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Van%22%2C%22lastName%22%3A%22Ingen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-03-01%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2016.09.006%22%2C%22ISSN%22%3A%221198-743X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.clinicalmicrobiologyandinfection.com%5C%2Farticle%5C%2FS1198-743X%2816%2930393-7%5C%2Ffulltext%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-12T09%3A40%3A21Z%22%7D%7D%2C%7B%22key%22%3A%226HBGRHS2%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Appelgren%20et%20al.%22%2C%22parsedDate%22%3A%222017-06-30%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAppelgren%2C%20A.%2C%20Morquin%2C%20D.%2C%20Dufour%2C%20S.%2C%20Le%20Moing%2C%20V.%2C%20Reynes%2C%20J.%2C%20Lotth%26%23xE9%3B%2C%20A.%2C%20Parer%2C%20S.%2C%20Corbeau%2C%20C.%2C%20Aubry%2C%20A.%2C%20Sougakoff%2C%20W.%2C%20Solassol%2C%20J.%2C%20Bonzon%2C%20L.%2C%20Dumont%2C%20Y.%20and%20Godreuil%2C%20S.%20%282017%29.%20%3Cb%3EInvestigation%20of%20pre-XDR%20Beijing%20Mycobacterium%20tuberculosis%20transmission%20to%20a%20healthcare%20worker%20in%20France%2C%202016%3C%5C%2Fb%3E.%20Journal%20of%20Hospital%20Infection%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jhin.2017.06.030%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jhin.2017.06.030%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Investigation%20of%20pre-XDR%20Beijing%20Mycobacterium%20tuberculosis%20transmission%20to%20a%20healthcare%20worker%20in%20France%2C%202016%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Appelgren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Morquin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Dufour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Le%20Moing%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Reynes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Lotth%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Parer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Corbeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Solassol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Bonzon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Dumont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Godreuil%22%7D%5D%2C%22abstractNote%22%3A%22A%20case%20of%20occupational%20contamination%20of%20a%20healthcare%20worker%20by%20a%20pre-extensively%20drug-resistant%20%28pre-XDR%29%20Beijing%20strain%20of%20Mycobacterium%20tuberculosis%20at%20the%20University%20Hospital%20of%20Montpellier%2C%20France%20is%20reported.%20The%20index%20case%20was%20identified%20using%20genetic%20fingerprinting%20of%20isolates.%20This%20report%20underscores%20the%20risk%20of%20healthcare-associated%20contamination%20by%20pre-XDR%20tuberculosis%20%28TB%29%20in%20low-incidence%20countries%20and%20the%20importance%20of%20molecular%20tools%20for%20TB%20care.%20It%20also%20calls%20for%20increased%20vigilance%20in%20the%20management%20of%20multi-drug-resistant%5C%2FXDR%20TB%20patients.%22%2C%22date%22%3A%22June%2030%2C%202017%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jhin.2017.06.030%22%2C%22ISSN%22%3A%220195-6701%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0195670117303778%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-09-08T16%3A22%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22WURBXHFN%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Aubry%20et%20al.%22%2C%22parsedDate%22%3A%222017-04-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAubry%2C%20A.%2C%20Mougari%2C%20F.%2C%20Reibel%2C%20F.%20and%20Cambau%2C%20E.%20%282017%29.%20%3Cb%3EMycobacterium%20marinum%3C%5C%2Fb%3E.%20Microbiology%20Spectrum%20%3Ci%3E5%3C%5C%2Fi%3E%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2Fmicrobiolspec.TNMI7-0038-2016%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2Fmicrobiolspec.TNMI7-0038-2016%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mycobacterium%20marinum%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Reibel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22Mycobacterium%20marinum%20is%20a%20well-known%20pathogenic%20mycobacterium%20for%20skin%20and%20soft%20tissue%20infections%20and%20is%20associated%20with%20fishes%20and%20water.%20Among%20nontuberculous%20mycobacteria%20%28NTM%29%2C%20it%20is%20the%20leading%20cause%20of%20extrarespiratory%20human%20infections%20worldwide.%20In%20addition%2C%20there%20is%20a%20specific%20scientific%20interest%20in%20M.%20marinum%20because%20of%20its%20genetic%20relatedness%20to%20Mycobacterium%20tuberculosis%20and%20because%20experimental%20infection%20of%20M.%20marinum%20in%20fishes%20mimics%20tuberculosis%20pathogenesis.%20Microbiological%20characteristics%20include%20the%20fact%20that%20it%20grows%20in%207%20to%2014%20days%20with%20photochromogenic%20colonies%20and%20is%20difficult%20to%20differentiate%20from%20Mycobacterium%20ulcerans%20and%20other%20mycolactone-producing%20NTM%20on%20a%20molecular%20basis.%20The%20diagnosis%20is%20highly%20suspected%20by%20the%20mode%20of%20infection%2C%20which%20is%20related%20to%20the%20hobby%20of%20fishkeeping%2C%20professional%20handling%20of%20marine%20shells%2C%20or%20swimming%20in%20nonchlorinated%20pools.%20Clinics%20distinguished%20skin%20and%20soft%20tissue%20lesions%20%28typically%20sporotrichoid%20or%20subacute%20hand%20nodules%29%20and%20lesions%20disseminated%20to%20joint%20and%20bone%2C%20often%20related%20with%20the%20local%20use%20of%20corticosteroids.%20In%20clinical%20microbiology%2C%20microscopy%20and%20culture%20are%20often%20negative%20because%20growth%20requires%20low%20temperature%20%2830%5Cu00b0C%29%20and%20several%20weeks%20to%20succeed%20in%20primary%20cultivation.%20The%20treatment%20is%20not%20standardized%2C%20and%20no%20randomized%20control%20trials%20have%20been%20done.%20Therapy%20is%20a%20combination%20of%20surgery%20and%20antimicrobial%20agents%20such%20as%20cyclines%20and%20rifampin%2C%20with%20successful%20outcome%20in%20most%20of%20the%20skin%20diseases%20but%20less%20frequently%20in%20deep%20tissue%20infections.%20Prevention%20can%20be%20useful%20with%20hand%20protection%20recommendations%20for%20professionals%20and%20all%20persons%20manipulating%20fishes%20or%20fish%20tank%20water%20and%20use%20of%20alcohol%20disinfection%20after%20contact.%22%2C%22date%22%3A%222017-04-07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1128%5C%2Fmicrobiolspec.TNMI7-0038-2016%22%2C%22ISSN%22%3A%222165-0497%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.asmscience.org%5C%2Fcontent%5C%2Fjournal%5C%2Fmicrobiolspec%5C%2F10.1128%5C%2Fmicrobiolspec.TNMI7-0038-2016%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222019-04-03T22%3A21%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22TDU55DMW%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bouchet%20et%20al.%22%2C%22parsedDate%22%3A%222017-08-16%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBouchet%2C%20F.%2C%20Martin%2C%20B.%2C%20Aubry%2C%20A.%2C%20Veziris%2C%20N.%2C%20Lavigne%2C%20J.-P.%20and%20Sotto%2C%20A.%20%282017%29.%20%3Cb%3EShould%20single%20antibiotic%20therapy%20be%20avoided%20for%20nontuberculous%20mycobacteria%3F%3C%5C%2Fb%3E%20M%26%23xE9%3Bdecine%20et%20Maladies%20Infectieuses%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.medmal.2017.07.004%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.medmal.2017.07.004%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Should%20single%20antibiotic%20therapy%20be%20avoided%20for%20nontuberculous%20mycobacteria%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Bouchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20-P.%22%2C%22lastName%22%3A%22Lavigne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Sotto%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22August%2016%2C%202017%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.medmal.2017.07.004%22%2C%22ISSN%22%3A%220399-077X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0399077X17301075%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-09-08T16%3A04%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22TUBJZW4P%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brossier%20and%20Sougakoff%22%2C%22parsedDate%22%3A%222017-09-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBrossier%2C%20F.%20and%20Sougakoff%2C%20W.%20%282017%29.%20%3Cb%3EMolecular%20detection%20methods%20of%20resistance%20to%20antituberculosis%20drugs%20in%20Mycobacterium%20tuberculosis%3C%5C%2Fb%3E.%20M%26%23xE9%3Bdecine%20et%20Maladies%20Infectieuses%20%3Ci%3E47%3C%5C%2Fi%3E%2C%20340%26%23x2013%3B348%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.medmal.2017.04.008%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.medmal.2017.04.008%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Molecular%20detection%20methods%20of%20resistance%20to%20antituberculosis%20drugs%20in%20Mycobacterium%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Sougakoff%22%7D%5D%2C%22abstractNote%22%3A%22Molecular%20methods%20predict%20drug%20resistance%20several%20weeks%20before%20phenotypic%20methods%20and%20enable%20rapid%20implementation%20of%20appropriate%20therapeutic%20treatment.%20We%20aimed%20to%20detail%20the%20most%20representative%20molecular%20tools%20used%20in%20routine%20practice%20for%20the%20rapid%20detection%20of%20resistance%20to%20antituberculosis%20drugs%20among%20Mycobacterium%20tuberculosis%20strains.%20The%20molecular%20diagnosis%20of%20resistance%20to%20antituberculosis%20drugs%20in%20clinical%20samples%20or%20from%20in%20vitro%20cultures%20is%20based%20on%20the%20detection%20of%20the%20most%20common%20mutations%20in%20the%20genes%20involved%20in%20the%20development%20of%20resistance%20in%20M.%20tuberculosis%20strains%20%28encoding%20either%20protein%20targets%20of%20antibiotics%2C%20or%20antibiotic%20activating%20enzymes%29%20by%20commercial%20molecular%20kits%20or%20by%20sequencing.%20Three%20hypotheses%20could%20explain%20the%20discrepancies%20between%20the%20genotypic%20results%20and%20the%20phenotypic%20drug%20susceptibility%20testing%20results%3A%20a%20low%20percentage%20of%20resistant%20mutants%20precluding%20the%20detection%20by%20genotypic%20methods%20on%20the%20primary%20culture%3B%20a%20low%20level%20of%20resistance%20not%20detected%20by%20phenotypic%20testing%3B%20and%20other%20resistance%20mechanisms%20not%20yet%20characterized.%20Molecular%20methods%20have%20varying%20sensitivity%20with%20regards%20to%20detecting%20antituberculosis%20drug%20resistance%3B%20that%20is%20why%20phenotypic%20susceptibility%20testing%20methods%20are%20mandatory%20for%20detecting%20antituberculosis%20drug-resistant%20isolates%20that%20have%20not%20been%20detected%20by%20molecular%20methods.%20The%20questionable%20ability%20of%20existing%20phenotypic%20and%20genotypic%20drug%20susceptibility%20testing%20to%20properly%20classify%20strains%20as%20susceptible%20or%20resistant%2C%20and%20at%20what%20level%20of%20resistance%2C%20was%20raised%20for%20several%20antituberculosis%20agents.%5CnLes%20m%5Cu00e9thodes%20mol%5Cu00e9culaires%20peuvent%20pr%5Cu00e9dire%20la%20r%5Cu00e9sistance%20aux%20antituberculeux%20plusieurs%20semaines%20avant%20les%20m%5Cu00e9thodes%20ph%5Cu00e9notypiques.%20Elles%20permettent%20une%20mise%20en%20place%20rapide%20du%20traitement%20th%5Cu00e9rapeutique%20ad%5Cu00e9quat.%20Notre%20but%20%5Cu00e9tait%20de%20d%5Cu00e9tailler%20les%20outils%20mol%5Cu00e9culaires%20les%20plus%20utilis%5Cu00e9s%20en%20routine%20pour%20la%20d%5Cu00e9tection%20rapide%20de%20la%20r%5Cu00e9sistance%20aux%20antituberculeux%20chez%20Mycobacterium%20tuberculosis.%20Le%20diagnostic%20mol%5Cu00e9culaire%20de%20la%20r%5Cu00e9sistance%20aux%20antituberculeux%20dans%20les%20pr%5Cu00e9l%5Cu00e8vements%20cliniques%20ou%20les%20cultures%20s%5Cu2019appuie%20sur%20la%20d%5Cu00e9tection%20des%20mutations%20les%20plus%20fr%5Cu00e9quentes%20dans%20les%20g%5Cu00e8nes%20incrimin%5Cu00e9s%20dans%20la%20r%5Cu00e9sistance%20chez%20M.%20tuberculosis%20%28codant%20les%20prot%5Cu00e9ines%20cibles%20ou%20les%20enzymes%20activatrices%20des%20antibiotiques%29%20par%20des%20kits%20commerciaux%20et%5C%2Fou%20par%20s%5Cu00e9quen%5Cu00e7age.%20Trois%20raisons%20peuvent%20expliquer%20des%20diff%5Cu00e9rences%20entre%20les%20r%5Cu00e9sultats%20des%20tests%20de%20sensibilit%5Cu00e9%20g%5Cu00e9notypique%20et%20ph%5Cu00e9notypique%3A%20un%20faible%20pourcentage%20de%20mutants%20r%5Cu00e9sistants%20emp%5Cu00eachant%20la%20d%5Cu00e9tection%20de%20la%20r%5Cu00e9sistance%20par%20m%5Cu00e9thode%20g%5Cu00e9notypique%20sur%20la%20culture%20primaire%3B%20un%20bas%20niveau%20de%20r%5Cu00e9sistance%20non%20d%5Cu00e9tect%5Cu00e9e%20par%20test%20ph%5Cu00e9notypique%3B%20d%5Cu2019autres%20m%5Cu00e9canismes%20de%20r%5Cu00e9sistance%20non%20encore%20%5Cu00e9lucid%5Cu00e9s.%20Les%20m%5Cu00e9thodes%20mol%5Cu00e9culaires%20ont%20des%20sensibilit%5Cu00e9s%20variables%20pour%20la%20d%5Cu00e9tection%20de%20la%20r%5Cu00e9sistance%20aux%20antituberculeux%2C%20c%5Cu2019est%20pourquoi%20les%20tests%20de%20sensibilit%5Cu00e9%20ph%5Cu00e9notypiques%20restent%20obligatoires%20pour%20d%5Cu00e9tecter%20les%20souches%20r%5Cu00e9sistantes%20aux%20antituberculeux%20non%20d%5Cu00e9tect%5Cu00e9es%20par%20les%20m%5Cu00e9thodes%20g%5Cu00e9notypiques.%20La%20capacit%5Cu00e9%20des%20tests%20de%20sensibilit%5Cu00e9%20ph%5Cu00e9notypiques%20et%20g%5Cu00e9notypiques%20%5Cu00e0%20classer%20correctement%20les%20souches%20comme%20sensibles%20et%20r%5Cu00e9sistantes%2C%20et%20%5Cu00e0%20quel%20niveau%20de%20r%5Cu00e9sistance%2C%20a%20%5Cu00e9t%5Cu00e9%20soulev%5Cu00e9e%20pour%20plusieurs%20antituberculeux.%22%2C%22date%22%3A%22September%201%2C%202017%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.medmal.2017.04.008%22%2C%22ISSN%22%3A%220399-077X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0399077X1730608X%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-02T14%3A41%3A22Z%22%7D%7D%2C%7B%22key%22%3A%225CRH6I5W%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brossier%20et%20al.%22%2C%22parsedDate%22%3A%222017-02-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBrossier%2C%20F.%2C%20Pham%2C%20A.%2C%20Bernard%2C%20C.%2C%20Aubry%2C%20A.%2C%20Jarlier%2C%20V.%2C%20Veziris%2C%20N.%2C%20Sougakoff%2C%20W.%20and%20CNR-MyRMA%2C%20O.%20B.%20of%20T.%20%282017%29.%20%3Cb%3EMolecular%20Investigation%20of%20Resistance%20to%20Second-Line%20Injectable%20Drugs%20in%20Multidrug-Resistant%20Clinical%20Isolates%20of%20Mycobacterium%20tuberculosis%20in%20France%3C%5C%2Fb%3E.%20Antimicrob%20Agents%20Chemother%20%3Ci%3E61%3C%5C%2Fi%3E%2C%20e01299-16%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.01299-16%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.01299-16%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Molecular%20Investigation%20of%20Resistance%20to%20Second-Line%20Injectable%20Drugs%20in%20Multidrug-Resistant%20Clinical%20Isolates%20of%20Mycobacterium%20tuberculosis%20in%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22On%20Behalf%20of%20The%22%2C%22lastName%22%3A%22CNR-MyRMA%22%7D%5D%2C%22abstractNote%22%3A%22The%20second-line%20injectable%20drugs%20%28SLID%2C%20i.e.%2C%20amikacin%2C%20kanamycin%2C%20capreomycin%29%20are%20key%20drugs%20for%20the%20treatment%20of%20multidrug-resistant%20tuberculosis.%20Mutations%20in%20rrs%20region%201400%2C%20tlyA%2C%20and%20eis%20promoter%20are%20associated%20with%20resistance%20to%20SLID%2C%20to%20capreomycin%2C%20and%20to%20kanamycin%2C%20respectively.%20In%20this%20study%2C%20the%20sequencing%20data%20of%20SLID%20resistance-associated%20genes%20were%20compared%20to%20the%20results%20of%20phenotypic%20drug%20susceptibility%20testing%20by%20the%20proportion%20method%20for%20the%20SLID%20in%20206%20multidrug-resistant%20clinical%20isolates%20of%20Mycobacterium%20tuberculosis%20collected%20in%20France.%20Among%20the%20153%20isolates%20susceptible%20to%20the%203%20SLID%2C%20145%20showed%20no%20mutation%2C%201%20harbored%20T1404C%20and%20G1473A%20mutations%20in%20rrs%2C%20and%207%20had%20an%20eis%20promoter%20mutation.%20Among%20the%2053%20strains%20resistant%20to%20at%20least%201%20of%20the%20SLID%2C%20mutations%20in%20rrs%20accounted%20for%20resistance%20to%20amikacin%2C%20capreomycin%2C%20and%20kanamycin%20for%2081%25%2C%2075%25%2C%20and%2044%25%20of%20the%20isolates%2C%20respectively%2C%20while%20mutations%20in%20eis%20promoter%20were%20detected%20in%2044%25%20of%20the%20isolates%20resistant%20to%20kanamycin.%20In%20contrast%2C%20no%20mutations%20in%20tlyA%20were%20observed%20in%20the%20isolates%20resistant%20to%20capreomycin.%20The%20discrepancies%20observed%20between%20the%20genotypic%20%28on%20the%20primary%20culture%29%20and%20phenotypic%20drug%20susceptibility%20testing%20were%20explained%20by%20%28i%29%20resistance%20to%20SLID%20with%20MICs%20close%20to%20the%20critical%20concentration%20used%20for%20routine%20DST%20and%20not%20detected%20by%20phenotypic%20testing%20%28n%20%3D%208%2C%2015%25%20of%20SLID-resistant%20strains%29%2C%20%28ii%29%20low-frequency%20heteroresistance%20not%20detected%20by%20sequencing%20of%20drug%20resistance-associated%20genes%20on%20the%20primary%20culture%20%28n%20%3D%208%2C%2015%25%20of%20SLID-resistant%20strains%29%2C%20and%20%28iii%29%20other%20resistance%20mechanisms%20not%20yet%20characterized%20%28n%20%3D%207%2C%2013%25%20of%20SLID-resistant%20strains%29.%22%2C%22date%22%3A%2202%5C%2F01%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.01299-16%22%2C%22ISSN%22%3A%220066-4804%2C%201098-6596%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Faac.asm.org%5C%2Fcontent%5C%2F61%5C%2F2%5C%2Fe01299-16%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-02T14%3A40%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22TDUI6NFB%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Delafont%20et%20al.%22%2C%22parsedDate%22%3A%222017-04-10%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDelafont%2C%20V.%2C%20Samba-Louaka%2C%20A.%2C%20Cambau%2C%20E.%2C%20Bouchon%2C%20D.%2C%20Moulin%2C%20L.%20and%20H%26%23xE9%3Bchard%2C%20Y.%20%282017%29.%20%3Cb%3EMycobacterium%20llatzerense%2C%20a%20waterborne%20Mycobacterium%2C%20that%20resists%20phagocytosis%20by%20Acanthamoeba%20castellanii%3C%5C%2Fb%3E.%20Scientific%20Reports%20%3Ci%3E7%3C%5C%2Fi%3E%2C%2046270%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fsrep46270%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fsrep46270%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mycobacterium%20llatzerense%2C%20a%20waterborne%20Mycobacterium%2C%20that%20resists%20phagocytosis%20by%20Acanthamoeba%20castellanii%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Delafont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ascel%22%2C%22lastName%22%3A%22Samba-Louaka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Bouchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22H%5Cu00e9chard%22%7D%5D%2C%22abstractNote%22%3A%22Nontuberculous%20mycobacteria%20%28NTM%29%20are%20environmental%20bacteria%20increasingly%20associated%20to%20public%20health%20problems.%20In%20water%20systems%2C%20free-living%20amoebae%20%28FLA%29%20feed%20on%20bacteria%20by%20phagocytosis%2C%20but%20several%20bacteria%2C%20including%20many%20NTM%2C%20are%20resistant%20to%20this%20predation.%20Thus%2C%20FLA%20can%20be%20seen%20as%20a%20training%20ground%20for%20pathogenic%20bacteria.%20Mycobacterium%20llatzerense%20was%20previously%20described%20as%20frequently%20associated%20with%20FLA%20in%20a%20drinking%20water%20network.%20The%20present%20study%20aimed%20to%20characterize%20the%20interactions%20between%20M.%20llatzerense%20and%20FLA.%20M.%20llatzerense%20was%20internalised%20by%20phagocytosis%20and%20featured%20lipid%20inclusions%2C%20suggesting%20a%20subversion%20of%20host%20resources.%20Moreover%2C%20M.%20llatzerense%20survived%20and%20even%20multiplied%20in%20presence%20of%20A.%20castellanii.%20Using%20a%20genomic-based%20comparative%20approach%2C%20twelve%20genes%20involved%20in%20phagocytosis%20interference%2C%20described%20in%20M.%20tuberculosis%2C%20were%20identified%20in%20the%20M.%20llatzerense%20genome%20sequenced%20in%20this%20study.%20Transcriptomic%20analyses%20showed%20that%20ten%20genes%20were%20significantly%20upregulated%20during%20the%20first%20hours%20of%20the%20infection%2C%20which%20could%20partly%20explain%20M.%20llatzerense%20resistance.%20Additionally%2C%20M.%20llatzerense%20was%20shown%20to%20actively%20inhibit%20phagosome%20acidification.%20In%20conclusion%2C%20M.%20llatzerense%20presents%20a%20high%20degree%20of%20resistance%20to%20phagocytosis%2C%20likely%20explaining%20its%20frequent%20occurrence%20within%20FLA%20in%20drinking%20water%20networks.%20It%20underscores%20that%20NTM%20should%20be%20carefully%20monitored%20in%20water%20networks%20to%20prevent%20human%20health%20concerns.%22%2C%22date%22%3A%222017-04-10%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fsrep46270%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fsrep46270%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222019-04-03T22%3A29%3A21Z%22%7D%7D%2C%7B%22key%22%3A%227WBDJD2A%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fournier%20et%20al.%22%2C%22parsedDate%22%3A%222017-09-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFournier%2C%20A.%2C%20Bernard%2C%20C.%2C%20Sougakoff%2C%20W.%2C%20Quelet%2C%20S.%2C%20Antoun%2C%20F.%2C%20Charlois-Ou%2C%20C.%2C%20Dormant%2C%20I.%2C%20Dufour%2C%20M.-O.%2C%20Hocine%2C%20N.%2C%20Jarlier%2C%20V.%20and%20Veziris%2C%20N.%20%282017%29.%20%3Cb%3ENeither%20genotyping%20nor%20contact%20tracing%20allow%20correct%20understanding%20of%20multidrug-resistant%20tuberculosis%20transmission%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E50%3C%5C%2Fi%3E%2C%201700891%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00891-2017%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00891-2017%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Neither%20genotyping%20nor%20contact%20tracing%20allow%20correct%20understanding%20of%20multidrug-resistant%20tuberculosis%20transmission%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%22%2C%22lastName%22%3A%22Fournier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Quelet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fadi%22%2C%22lastName%22%3A%22Antoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Charlois-Ou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Dormant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Odile%22%2C%22lastName%22%3A%22Dufour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nora%22%2C%22lastName%22%3A%22Hocine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22Tweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetEven%20combined%20contact%20tracing%20and%20genotyping%20fail%20to%20explain%20how%20MDR-TB%20transmission%20occurs%20in%20one%20third%20of%20cases%20http%3A%5C%2F%5C%2Fow.ly%5C%2F2ZKB30dRVGw%22%2C%22date%22%3A%222017%5C%2F09%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00891-2017%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F50%5C%2F3%5C%2F1700891%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222019-04-03T22%3A43%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22E28WQ94R%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20et%20al.%22%2C%22parsedDate%22%3A%222017-03-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuglielmetti%2C%20L.%2C%20Jaspard%2C%20M.%2C%20D%26%23xFB%3B%2C%20D.%20L.%2C%20Lach%26%23xE2%3Btre%2C%20M.%2C%20Marigot-Outtandy%2C%20D.%2C%20Bernard%2C%20C.%2C%20Veziris%2C%20N.%2C%20Robert%2C%20J.%2C%20Yazdanpanah%2C%20Y.%2C%20Caumes%2C%20E.%20and%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%20%282017%29.%20%3Cb%3ELong-term%20outcome%20and%20safety%20of%20prolonged%20bedaquiline%20treatment%20for%20multidrug-resistant%20tuberculosis%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E49%3C%5C%2Fi%3E%2C%201601799%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.01799-2016%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.01799-2016%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20outcome%20and%20safety%20of%20prolonged%20bedaquiline%20treatment%20for%20multidrug-resistant%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Jaspard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%20Le%22%2C%22lastName%22%3A%22D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Lach%5Cu00e2tre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhiba%22%2C%22lastName%22%3A%22Marigot-Outtandy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yazdan%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%5D%2C%22abstractNote%22%3A%22Bedaquiline%2C%20a%20recently%20approved%20drug%20for%20the%20treatment%20of%20multidrug-resistant%20tuberculosis%20%28MDR-TB%29%2C%20is%20recommended%20for%20a%20duration%20of%2024%20weeks.%20There%20are%20scarce%20data%20on%20patients%20treated%20with%20this%20drug%20outside%20clinical%20trials.%5CnAll%20MDR-TB%20patients%20who%20started%20treatment%20from%20January%201%2C%202011%20to%20December%2031%2C%202013%20and%20received%20%5Cu226530%20days%20of%20bedaquiline%20were%20included%20in%20a%20multicentre%20observational%20cohort.%5CnAmong%2045%20MDR-TB%20patients%2C%2053%25%20harboured%20isolates%20resistant%20to%20both%20fluoroquinolones%20and%20second-line%20injectables%2C%20and%2038%25%20harboured%20isolates%20resistant%20to%20one%20of%20these%20drug%20classes.%20Median%20bedaquiline%20treatment%20duration%20was%20361%20days%20and%2033%20patients%20%2873%25%29%20received%20prolonged%20%28%3E190%20days%29%20bedaquiline%20treatment.%20Overall%2C%2036%20patients%20%2880%25%29%20had%20favourable%20outcome%2C%20five%20were%20lost%20to%20follow-up%2C%20three%20died%2C%20and%20one%20failed%20and%20acquired%20bedaquiline%20resistance.%20No%20cases%20of%20recurrence%20were%20reported.%20Severe%20and%20serious%20adverse%20events%20were%20recorded%20in%2060%25%20and%2018%25%20of%20patients%2C%20respectively.%20Values%20of%20Fridericia-corrected%20QT%20interval%20%28QTcF%29%20%3E500%20ms%20were%20recorded%20in%2011%25%20of%20patients%2C%20but%20neither%20arrhythmias%20nor%20symptomatic%20cardiac%20side-effects%20occurred.%20Bedaquiline%20was%20discontinued%20in%20three%20patients%20following%20QTcF%20prolongation.%20No%20significant%20differences%20in%20outcomes%20or%20adverse%20events%20rates%20were%20observed%20between%20patients%20receiving%20standard%20and%20prolonged%20bedaquiline%20treatment.%5CnBedaquiline-containing%20regimens%20achieved%20favourable%20outcomes%20in%20a%20large%20proportion%20of%20patients.%20Prolonged%20bedaquiline%20treatment%20was%20overall%20well%20tolerated%20in%20this%20cohort.%5CnTweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetTreatment%20regimens%20including%20prolonged%20bedaquiline%20use%20are%20effective%20and%20overall%20well%20tolerated%20in%20MDR-TB%20patients%20http%3A%5C%2F%5C%2Fow.ly%5C%2Fvhtl305CYJj%22%2C%22date%22%3A%222017%5C%2F03%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.01799-2016%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F49%5C%2F3%5C%2F1601799%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222019-04-01T16%3A42%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22342DZFUU%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20et%20al.%22%2C%22parsedDate%22%3A%222017-02-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuglielmetti%2C%20L.%2C%20Hewison%2C%20C.%2C%20Avaliani%2C%20Z.%2C%20Hughes%2C%20J.%2C%20Kiria%2C%20N.%2C%20Lomtadze%2C%20N.%2C%20Ndjeka%2C%20N.%2C%20Setkina%2C%20S.%2C%20Shabangu%2C%20A.%2C%20Sikhondze%2C%20W.%2C%20Skrahina%2C%20A.%2C%20Veziris%2C%20N.%20and%20Furin%2C%20J.%20%282017%29.%20%3Cb%3EExamples%20of%20bedaquiline%20introduction%20for%20the%20management%20of%20multidrug-resistant%20tuberculosis%20in%20five%20countries%3C%5C%2Fb%3E.%20The%20International%20Journal%20of%20Tuberculosis%20and%20Lung%20Disease%20%3Ci%3E21%3C%5C%2Fi%3E%2C%20167%26%23x2013%3B174%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.16.0493%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.16.0493%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Examples%20of%20bedaquiline%20introduction%20for%20the%20management%20of%20multidrug-resistant%20tuberculosis%20in%20five%20countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Hewison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z.%22%2C%22lastName%22%3A%22Avaliani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Hughes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Kiria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Lomtadze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Ndjeka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Setkina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Shabangu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Sikhondze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Furin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20For%20the%20first%20time%20in%20almost%2050%20years%2C%20there%20are%20new%20drugs%20available%20for%20the%20treatment%20of%20tuberculosis%20%28TB%29%2C%20including%20bedaquiline%20%28BDQ%29%20and%20delamanid%20%28DLM%29.%20The%20rate%20of%20introduction%2C%20however%2C%20has%20not%20kept%20pace%20with%20patient%20needs.%20It%20is%20estimated%20that%20as%20many%20as%2023%25%20of%20multidrug-resistant%20TB%20%28MDR-TB%29%20patients%20have%20an%20indication%20for%20receiving%20BDQ.%20As%20this%20is%20the%20first%20time%20the%20MDR-TB%20community%20is%20introducing%20new%20medications%2C%20it%20is%20important%20to%20understand%20how%20implementation%20can%20be%20developed%20in%20a%20variety%20of%20settings.METHODS%3A%20A%20qualitative%20assessment%20of%20country%20TB%20programs%20in%20which%20more%20than%205%25%20of%20MDR-TB%20patients%20were%20started%20on%20BDQ%20under%20program%20conditions.RESULTS%3A%20National%20TB%20programs%20in%20Belarus%2C%20France%2C%20Georgia%2C%20South%20Africa%2C%20and%20Swaziland%20all%20started%20sizeable%20cohorts%20of%20patients%20on%20BDQ%20in%202015.%20Common%20factors%20observed%20in%20these%20programs%20included%20experience%20with%20compassionate%20use%5C%2Fexpanded%20access%2C%20support%20from%20implementing%20partners%2C%20and%20adequate%20national%20or%20donor-supported%20budgets.%20Barriers%20to%20introduction%20included%20restriction%20of%20BDQ%20to%20the%20in-patient%20setting%2C%20lack%20of%20access%20to%20companion%20drugs%2C%20and%20the%20development%20of%20systems%20for%20pharmacovigilance.CONCLUSION%3A%20The%20five%20countries%20in%20this%20paper%20are%20examples%20of%20the%20introduction%20of%20new%20therapeutic%20options%20for%20the%20treatment%20of%20TB.%22%2C%22date%22%3A%222017-02-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.16.0493%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-02T14%3A40%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22W93AX45N%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jaspard%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EJaspard%2C%20M.%2C%20Elefant-Amoura%2C%20E.%2C%20Melonio%2C%20I.%2C%20de%20Montgolfier%2C%20I.%2C%20Veziris%2C%20N.%20and%20Caumes%2C%20E.%20%282017%29.%20%3Cb%3EBedaquiline%20and%20Linezolid%20for%20Extensively%20Drug-Resistant%20Tuberculosis%20in%20Pregnant%20Woman%3C%5C%2Fb%3E.%20Emerging%20Infect%20Dis%20%3Ci%3E23%3C%5C%2Fi%3E%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2310.161398%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2310.161398%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Bedaquiline%20and%20Linezolid%20for%20Extensively%20Drug-Resistant%20Tuberculosis%20in%20Pregnant%20Woman%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Jaspard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Elefant-Amoura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Melonio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22de%20Montgolfier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Caumes%22%7D%5D%2C%22abstractNote%22%3A%22A%20woman%20with%20extremely%20drug-resistant%20tuberculosis%20treated%20with%20a%20drug%20regimen%20including%20linezolid%20and%20bedaquiline%20during%20her%20last%203%20weeks%20of%20pregnancy%20gave%20birth%20to%20a%20child%20without%20abnormalities.%20No%20fetal%20toxicities%20were%20noted%20by%202%20years%20after%20delivery.%20This%20drug%20combination%20might%20be%20safe%20during%20the%20late%20third%20trimester%20of%20pregnancy.%22%2C%22date%22%3A%222017%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3201%5C%2Feid2310.161398%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwwwnc.cdc.gov%5C%2Feid%5C%2Farticle%5C%2F23%5C%2F10%5C%2F16-1398_article%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222019-04-03T22%3A52%3A59Z%22%7D%7D%2C%7B%22key%22%3A%2283V4AFER%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Leyer%20et%20al.%22%2C%22parsedDate%22%3A%222017-07-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELeyer%2C%20C.%2C%20Gregorowicz%2C%20G.%2C%20Mougari%2C%20F.%2C%20Raskine%2C%20L.%2C%20Cambau%2C%20E.%20and%20Briel%2C%20D.%20de%20%282017%29.%20%3Cb%3EComparison%20of%20Saramis%204.12%20and%20IVD%203.0%20Vitek%20MS%20Matrix-Assisted%20Laser%20Desorption%20Ionization%26%23x2013%3BTime%20of%20Flight%20Mass%20Spectrometry%20for%20Identification%20of%20Mycobacteria%20from%20Solid%20and%20Liquid%20Culture%20Media%3C%5C%2Fb%3E.%20Journal%20of%20Clinical%20Microbiology%20%3Ci%3E55%3C%5C%2Fi%3E%2C%202045%26%23x2013%3B2054%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FJCM.00006-17%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FJCM.00006-17%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparison%20of%20Saramis%204.12%20and%20IVD%203.0%20Vitek%20MS%20Matrix-Assisted%20Laser%20Desorption%20Ionization%5Cu2013Time%20of%20Flight%20Mass%20Spectrometry%20for%20Identification%20of%20Mycobacteria%20from%20Solid%20and%20Liquid%20Culture%20Media%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Leyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Gregorowicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Raskine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%20de%22%2C%22lastName%22%3A%22Briel%22%7D%5D%2C%22abstractNote%22%3A%22During%20the%20last%20decade%2C%20many%20investigators%20have%20studied%20matrix-assisted%20laser%20desorption%20ionization%5Cu2013time%20of%20flight%20mass%20spectrometry%20%28MALDI-TOF%20MS%29%20for%20identification%20of%20mycobacteria.%20Diverse%20and%20contradictory%20results%20indicated%20that%20optimal%20level%20for%20routine%20testing%20has%20not%20been%20reached%20yet.%20This%20work%20aimed%20to%20assess%20Vitek%20MS%20through%20two%20distinct%20versions%2C%20Saramis%20v4.12%20RUO%20and%20the%20IVD%20v3.0%2C%20under%20conditions%20close%20to%20routine%20laboratory%20practice.%20Overall%2C%20111%20mycobacterial%20isolates%20were%20subjected%20to%20protein%20extraction%20and%20same%20spectra%20were%20matched%20against%20both%20databases.%20The%20IVD%20v3.0%20database%20proved%20to%20be%20superior%20to%20Saramis%20v4.12%20and%20its%20identification%20rates%20remarkably%20increased%2C%20from%2067%25%20to%2094%25%20for%20isolates%20grown%20on%20Middlebrook%207H10%20solid%20medium%20and%20from%2062%25%20to%2091%25%20for%20isolates%20grown%20on%20mycobacterial%20growth%20indicator%20tube%20%28MGIT%29%20liquid%20medium.%20With%20this%20new%20version%2C%20IVD%20v3.0%2C%20MALDI-TOF%20MS%20might%20be%20integrated%20into%20routine%20clinical%20diagnostics%2C%20although%20molecular%20techniques%20remain%20mandatory%20in%20some%20cases.%22%2C%22date%22%3A%222017%5C%2F07%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1128%5C%2FJCM.00006-17%22%2C%22ISSN%22%3A%220095-1137%2C%201098-660X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjcm.asm.org%5C%2Fcontent%5C%2F55%5C%2F7%5C%2F2045%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222019-04-03T22%3A17%3A11Z%22%7D%7D%2C%7B%22key%22%3A%225Q57TTXS%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitre%20et%20al.%22%2C%22parsedDate%22%3A%222017-12-14%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaitre%2C%20T.%2C%20Aubry%2C%20A.%20and%20Veziris%2C%20N.%20%282017%29.%20%3Cb%3EMolecular%20Drug-Susceptibility%20Test%20for%20Tuberculosis%3C%5C%2Fb%3E.%20New%20England%20Journal%20of%20Medicine%20%3Ci%3E377%3C%5C%2Fi%3E%2C%202403%26%23x2013%3B2404%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1056%5C%2FNEJMc1714218%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1056%5C%2FNEJMc1714218%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Molecular%20Drug-Susceptibility%20Test%20for%20Tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22To%20the%20Editor%3A%20Xie%20et%20al.%20%28Sept.%2014%20issue%291%20present%20the%20evaluation%20of%20a%20new%20molecular%20test%20for%20the%20detection%20of%20resistance%20of%20Mycobacterium%20tuberculosis%20to%20fluoroquinolones%2C%20aminoglycosides%2C%20and%20isoniazid.%20In%20the%20Discussion%20section%2C%20the%20authors%20mention%20that%20one%20of%20the%20limitations%20of%20their%20study%20is%20that%20the%20geographic%20representation%20is%20limited%20to%20China%20and%20South%20Korea.%20The%20geographic%20origin%20of%20a%20strain%20of%20M.%20tuberculosis%20is%20of%20particular%20importance%20for%20the%20interpretation%20of%20genotypic%20testing%20for%20drug%20resistance.%20For%20example%2C%20it%20has%20been%20shown%20that%20strains%20from%20the%20Congo%20area%20can%20be%20erroneously%20interpreted%20as%20fluoroquinolone-resistant%20with%20the%20GenoType%20.%20.%20.%22%2C%22date%22%3A%22December%2014%2C%202017%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1056%5C%2FNEJMc1714218%22%2C%22ISSN%22%3A%220028-4793%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1056%5C%2FNEJMc1714218%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222019-04-03T22%3A48%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22EQSSDJFH%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitre%20et%20al.%22%2C%22parsedDate%22%3A%222017-08-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaitre%2C%20T.%2C%20Petitjean%2C%20G.%2C%20Chauffour%2C%20A.%2C%20Bernard%2C%20C.%2C%20El%20Helali%2C%20N.%2C%20Jarlier%2C%20V.%2C%20Reibel%2C%20F.%2C%20Chavanet%2C%20P.%2C%20Aubry%2C%20A.%20and%20Veziris%2C%20N.%20%282017%29.%20%3Cb%3EAre%20moxifloxacin%20and%20levofloxacin%20equally%20effective%20to%20treat%20XDR%20tuberculosis%3F%3C%5C%2Fb%3E%20J%20Antimicrob%20Chemother%20%3Ci%3E72%3C%5C%2Fi%3E%2C%202326%26%23x2013%3B2333%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkx150%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkx150%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Are%20moxifloxacin%20and%20levofloxacin%20equally%20effective%20to%20treat%20XDR%20tuberculosis%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gr%5Cu00e9goire%22%2C%22lastName%22%3A%22Petitjean%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Najoua%22%2C%22lastName%22%3A%22El%20Helali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Reibel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Chavanet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%20Moxifloxacin%20retains%20partial%20activity%20against%20some%20fluoroquinolone-resistant%20mutants%20of%20Mycobacterium%20tuberculosis.%20Levofloxacin%20is%20presumed%20to%20be%20as%20active%20as%20moxifloxacin%20against%20drug-susceptible%20tuberculosis%20and%20to%20have%20a%20better%20safety%20profile.Objectives%3A%20To%20compare%20the%20in%20vivo%20activity%20of%20levofloxacin%20and%20moxifloxacin%20against%20M.%20tuberculosis%20strains%20with%20various%20levels%20of%20fluoroquinolone%20resistance.Methods%3A%20BALB%5C%2Fc%20mice%20were%20intravenously%20infected%20with%20106M.%20tuberculosis%20H37Rv%20and%20three%20isogenic%20mutants%3A%20GyrA%20A90V%2C%20GyrB%20E540A%20and%20GyrB%20A543V.%20Treatment%20with%2050%20or%20100%5Cu2009mg%5C%2Fkg%20levofloxacin%20and%2060%20or%2066%5Cu2009mg%5C%2Fkg%20moxifloxacin%20was%20given%20orally%20every%206%5Cu2009h%2C%20for%204%5Cu2009weeks.Results%3A%20Levofloxacin%2050%20and%20100%5Cu2009mg%5C%2Fkg%20q6h%20and%20moxifloxacin%2060%20and%2066%5Cu2009mg%5C%2Fkg%20q6h%20generated%20AUCs%20in%20mice%20equivalent%20to%20those%20of%20levofloxacin%20750%20and%201000%5Cu2009mg%5C%2Fday%20and%20moxifloxacin%20400%20and%20800%5Cu2009mg%5C%2Fday%2C%20respectively%2C%20in%20humans.%20Moxifloxacin%2060%20and%2066%5Cu2009mg%5C%2Fkg%20q6h%20had%20bactericidal%20activity%20against%20strain%20H37Rv%20%28MIC%5Cu2009%5Cu2264%5Cu20090.25%5Cu2009mg%5C%2FL%29%20and%20mutants%20GyrB%20E540A%20and%20GyrB%20A543V%20%28MIC%5Cu2009%3D%5Cu20090.5%5Cu2009mg%5C%2FL%29.%20Against%20mutant%20GyrA%20A90V%20%28MIC%5Cu2009%3D%5Cu20092%5Cu2009mg%5C%2FL%29%2C%20moxifloxacin%2060%5Cu2009mg%5C%2Fkg%20q6h%20did%20not%20prevent%20bacillary%20growth%2C%20whereas%2066%5Cu2009mg%5C%2Fkg%20q6h%20had%20bacteriostatic%20activity.%20Levofloxacin%2050%5Cu2009mg%5C%2Fkg%20q6h%20had%20bactericidal%20activity%20against%20H37Rv%20%28MIC%5Cu2009%5Cu2264%5Cu20090.25%5Cu2009mg%5C%2FL%29%20but%20not%20against%20the%20mutant%20strains.%20Levofloxacin%20100%5Cu2009mg%5C%2Fkg%20q6h%20had%20bactericidal%20activity%20against%20H37Rv%20and%20mutants%20GyrB%20E540A%20%28MIC%5Cu2009%3D%5Cu20090.5%5Cu2009mg%5C%2FL%29%20and%20GyrB%20A543V%20%28MIC%3D%5Cu20091%5Cu2009mg%5C%2FL%29%20but%20not%20against%20mutant%20GyrA%20A90V%20%28MIC%5Cu2009%3D%5Cu20094%5Cu2009mg%5C%2FL%29.Conclusions%3A%20All%20mutations%20reduced%20fluoroquinolone%20activity%2C%20even%20those%20classified%20as%20susceptible%20according%20to%20phenotypic%20tests.%20High-dose%20levofloxacin%20is%20less%20effective%20than%20high-dose%20moxifloxacin%20against%20both%20fluoroquinolone-resistant%20and%20-susceptible%20M.%20tuberculosis%20strains%20in%20mice.%22%2C%22date%22%3A%222017%5C%2F08%5C%2F01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fjac%5C%2Fdkx150%22%2C%22ISSN%22%3A%220305-7453%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fjac%5C%2Farticle%5C%2F72%5C%2F8%5C%2F2326%5C%2F3849381%5C%2FAre-moxifloxacin-and-levofloxacin-equally%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-02T14%3A41%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22TF36G6J8%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitre%20et%20al.%22%2C%22parsedDate%22%3A%222017-02-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaitre%2C%20T.%2C%20Aubry%2C%20A.%2C%20Jarlier%2C%20V.%2C%20Robert%2C%20J.%2C%20Veziris%2C%20N.%2C%20Bernard%2C%20C.%2C%20Sougakoff%2C%20W.%2C%20Brossier%2C%20F.%2C%20Cambau%2C%20E.%2C%20Mougari%2C%20F.%20and%20Raskine%2C%20L.%20%282017%29.%20%3Cb%3EMultidrug%20and%20extensively%20drug-resistant%20tuberculosis%3C%5C%2Fb%3E.%20M%26%23xE9%3Bdecine%20et%20Maladies%20Infectieuses%20%3Ci%3E47%3C%5C%2Fi%3E%2C%203%26%23x2013%3B10%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.medmal.2016.07.006%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.medmal.2016.07.006%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Multidrug%20and%20extensively%20drug-resistant%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Raskine%22%7D%5D%2C%22abstractNote%22%3A%22The%20emergence%20of%20drug-resistant%20tuberculosis%20%28TB%29%20compromises%20global%20tuberculosis%20control.%20The%20incidence%20of%20multidrug-resistant%20strains%20%28MDR%29%20defined%20as%20resistant%20to%20the%20two%20main%20antituberculosis%20drugs%2C%20rifampicin%20and%20isoniazid%2C%20was%20raised%20in%20the%201990s.%20Ten%20percent%20of%20these%20strains%20have%20developed%20additional%20resistance%20to%20the%20main%20second-line%20antituberculosis%20drugs%3A%20fluoroquinolones%20and%20aminoglycosides.%20These%20strains%20are%20defined%20as%20extensively%20drug-resistant%20%28XDR%29.%20The%20prognosis%20of%20MDR-TB%20and%20XDR-TB%20is%20poor%20due%20to%20limited%20therapeutic%20resources.%20However%2C%20many%20new%20innovations%20may%20lead%20to%20a%20radical%20change%20in%20this%20field.%20Genotypic%20testing%20is%20now%20able%20to%20detect%20drug%20resistance%20within%20a%20few%20hours.%20Genotypic%20diagnosis%20of%20rifampicin%20resistance%20is%20now%20recommended%20in%20France%20for%20each%20new%20case%20of%20TB.%20The%20currently%20recommended%20treatment%20for%20MDR-TB%20is%20long%20%2818%5Cu201324%5Cu00a0months%29%20and%20toxic.%20It%20is%2C%20however%2C%20on%20the%20verge%20of%20being%20replaced%20by%20a%209-month%20treatment.%20New%20antituberculosis%20drugs%20such%20as%20bedaquiline%20and%20delamanid%20should%20also%20improve%20the%20prognosis%20of%20MDR-TB%20and%20XDR-TB.%5CnR%5Cu00e9sum%5Cu00e9%5CnL%5Cu2019%5Cu00e9mergence%20des%20tuberculoses%20%28TB%29%20%5Cu00e0%20bacilles%20r%5Cu00e9sistants%20aux%20antituberculeux%20compromet%20le%20contr%5Cu00f4le%20mondial%20de%20la%20tuberculose.%20Les%20souches%20multir%5Cu00e9sistantes%20%28MDR%29%2C%20c%5Cu2019est-%5Cu00e0-dire%20r%5Cu00e9sistantes%20%5Cu00e0%20l%5Cu2019isoniazide%20et%20%5Cu00e0%20la%20rifampicine%2C%20sont%20apparues%20dans%20les%20ann%5Cu00e9es%5Cu00a090.%20Parmi%20ces%20souches%2C%2010%5Cu00a0%25%20ont%20d%5Cu00e9velopp%5Cu00e9%20des%20m%5Cu00e9canismes%20de%20r%5Cu00e9sistance%20suppl%5Cu00e9mentaires%20aux%20principaux%20antituberculeux%20de%20deuxi%5Cu00e8me%20ligne%5Cu00a0%3A%20les%20fluoroquinolones%20et%20les%20aminosides.%20Ces%20souches%20sont%20dites%20ultrar%5Cu00e9sistantes%20%28XDR%29.%20Le%20pronostic%20de%20ces%20tuberculoses%20est%20sombre%20compte%20tenu%20du%20peu%20de%20ressources%20th%5Cu00e9rapeutiques%20disponibles.%20Toutefois%2C%20de%20nombreuses%20nouveaut%5Cu00e9s%20permettent%20d%5Cu2019envisager%20un%20changement%20radical%20dans%20la%20prise%20en%20charge%20de%20ces%20cas.%20Sur%20le%20plan%20diagnostique%2C%20les%20tests%20g%5Cu00e9notypiques%20permettent%20de%20faire%20un%20diagnostic%20des%20r%5Cu00e9sistances%20aux%20antituberculeux%20en%20quelques%20heures.%20Il%20est%20d%5Cu00e9sormais%20recommand%5Cu00e9%20de%20r%5Cu00e9aliser%20un%20diagnostic%20g%5Cu00e9notypique%20de%20r%5Cu00e9sistance%20%5Cu00e0%20la%20rifampicine%20pour%20tout%20nouveau%20cas%20de%20tuberculose.%20Sur%20le%20plan%20th%5Cu00e9rapeutique%2C%20le%20traitement%20de%20r%5Cu00e9f%5Cu00e9rence%20actuel%20pour%20les%20cas%20MDR%2C%20qui%20est%20long%20%2818%5Cu00a0%5Cu00e0%2024%5Cu00a0mois%29%20et%20toxique%2C%20est%20en%20passe%20d%5Cu2019%5Cu00eatre%20remplac%5Cu00e9%20par%20un%20traitement%20court%20de%209%5Cu00a0mois.%20Enfin%2C%20de%20nouveaux%20antituberculeux%20comme%20la%20b%5Cu00e9daquiline%20et%20le%20delamanid%20offrent%20des%20perspectives%20d%5Cu2019am%5Cu00e9lioration%20du%20traitement%20des%20tuberculoses%20MDR%20et%20XDR.%22%2C%22date%22%3A%222017-02-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.medmal.2016.07.006%22%2C%22ISSN%22%3A%220399-077X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0399077X16301433%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-06-03T06%3A48%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22TTM3V9TD%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mazoyer%20et%20al.%22%2C%22parsedDate%22%3A%222017-03-13%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMazoyer%2C%20A.%2C%20Ycart%2C%20B.%20and%20Veziris%2C%20N.%20%282017%29.%20%3Cb%3ECorrection%3A%20Unbiased%20Estimation%20of%20Mutation%20Rates%20under%20Fluctuating%20Final%20Counts%3C%5C%2Fb%3E.%20PLOS%20ONE%20%3Ci%3E12%3C%5C%2Fi%3E%2C%20e0173143%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0173143%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0173143%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Correction%3A%20Unbiased%20Estimation%20of%20Mutation%20Rates%20under%20Fluctuating%20Final%20Counts%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrien%22%2C%22lastName%22%3A%22Mazoyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Ycart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2213%20mars%202017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0173143%22%2C%22ISSN%22%3A%221932-6203%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.plos.org%5C%2Fplosone%5C%2Farticle%3Fid%3D10.1371%5C%2Fjournal.pone.0173143%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222019-04-03T22%3A45%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22N2N9JDXB%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mougari%20et%20al.%22%2C%22parsedDate%22%3A%222017-06-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMougari%2C%20F.%2C%20Loiseau%2C%20J.%2C%20Veziris%2C%20N.%2C%20Bernard%2C%20C.%2C%20Bercot%2C%20B.%2C%20Sougakoff%2C%20W.%2C%20Jarlier%2C%20V.%2C%20Raskine%2C%20L.%20and%20Cambau%2C%20E.%20%282017%29.%20%3Cb%3EEvaluation%20of%20the%20new%20GenoType%20NTM-DR%20kit%20for%20the%20molecular%20detection%20of%20antimicrobial%20resistance%20in%20non-tuberculous%20mycobacteria%3C%5C%2Fb%3E.%20J%20Antimicrob%20Chemother%20%3Ci%3E72%3C%5C%2Fi%3E%2C%201669%26%23x2013%3B1677%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkx021%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkx021%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20the%20new%20GenoType%20NTM-DR%20kit%20for%20the%20molecular%20detection%20of%20antimicrobial%20resistance%20in%20non-tuberculous%20mycobacteria%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jade%22%2C%22lastName%22%3A%22Loiseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9atrice%22%2C%22lastName%22%3A%22Bercot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Raskine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22Objectives%3A%20Non-tuberculous%20mycobacteria%20%28NTM%29%20are%20emerging%20pathogens%20causing%20difficult-to-treat%20infections.%20We%20tested%20a%20new%20assay%20%28GenoType%20NTM-DR%29%20that%20detects%20natural%20and%20acquired%20resistance%20mechanisms%20to%20macrolides%20and%20aminoglycosides%20in%20frequently%20isolated%20NTM%20species.Methods%3A%20Performance%20was%20assessed%20on%20102%20isolates%20including%20reference%20strains%20%5B16%20Mycobacterium%20avium%2C%2010%20Mycobacterium%20intracellulare%2C%208%20Mycobacterium%20chimaera%2C%2015%20Mycobacterium%20chelonae%20and%2053%20Mycobacterium%20abscessus%20%28including%20subsp.%20abscessus%20isolates%2C%2018%20with%20a%20t28%20in%20erm%2841%29%20and%2010%20with%20a%20c28%2C%2013%20subsp.%20bolletii%20isolates%20and%2012%20subsp.%20massiliense%20isolates%29%5D.%20Genotypes%20were%20determined%20by%20PCR%20sequencing%20of%20erm%2841%29%20and%20rrl%20for%20clarithromycin%20resistance%20and%20of%20the%201400%5Cu20131480%20rrs%20region%20for%20aminoglycoside%20resistance.%20Phenotypes%20were%20determined%20by%20MIC%20microdilution.Results%3A%20GenoType%20NTM-DR%20yielded%20results%20concordant%20with%20Sanger%20sequencing%20for%20100%5C%2F102%20%2898%25%29%20isolates.%20The%20erm%2841%29%20genotypic%20pattern%20was%20accurately%20identified%20for%20M.%20abscessus%20isolates.%20Mutations%20in%20rrl%20were%20detected%20in%2015%20isolates%20%287%20M.%20avium%20complex%2C%205%20M.%20abscessus%20and%203%20M.%20chelonae%29%20with%20acquired%20clarithromycin%20resistance%20harbouring%20rrl%20mutations%20%28a2057c%2C%20a2058g%2C%20a2058t%20or%20a2059c%29.%20Mutations%20in%20rrs%20were%20detected%20in%20five%20isolates%20with%20amikacin%20resistance%20harbouring%20the%20rrs%20mutation%20a1408g.%20In%20two%20isolates%2C%20the%20NTM-DR%20test%20revealed%20an%20rrl%20mutation%20%28initial%20sequencing%20being%20WT%29%2C%20which%20was%20confirmed%20by%20re-sequencing.%20The%20test%20results%20were%20concordant%20with%20phenotypic%20susceptibility%20testing%20in%2096%5C%2F102%20%2894.1%25%29%20isolates%2C%20with%20four%20clarithromycin-resistant%20and%20two%20amikacin-resistant%20isolates%20not%20harbouring%20mutations.Conclusions%3A%20The%20GenoType%20NTM-DR%20test%20is%20efficient%20in%20detecting%20mutations%20predictive%20of%20antimicrobial%20resistance%20in%20M.%20avium%20complex%2C%20M.%20abscessus%20and%20M.%20chelonae.%22%2C%22date%22%3A%222017%5C%2F06%5C%2F01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fjac%5C%2Fdkx021%22%2C%22ISSN%22%3A%220305-7453%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fjac%5C%2Farticle%5C%2F72%5C%2F6%5C%2F1669%5C%2F3058522%5C%2FEvaluation-of-the-new-GenoType-NTM-DR-kit-for-the%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-02T14%3A40%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22U8TQ72Y2%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mougari%20et%20al.%22%2C%22parsedDate%22%3A%222017-01-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMougari%2C%20F.%2C%20Bouziane%2C%20F.%2C%20Crockett%2C%20F.%2C%20Nessar%2C%20R.%2C%20Chau%2C%20F.%2C%20Veziris%2C%20N.%2C%20Sapriel%2C%20G.%2C%20Raskine%2C%20L.%20and%20Cambau%2C%20E.%20%282017%29.%20%3Cb%3ESelection%20of%20Resistance%20to%20Clarithromycin%20in%20Mycobacterium%20abscessus%20Subspecies%3C%5C%2Fb%3E.%20Antimicrob%20Agents%20Chemother%20%3Ci%3E61%3C%5C%2Fi%3E%2C%20e00943-16%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00943-16%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00943-16%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Selection%20of%20Resistance%20to%20Clarithromycin%20in%20Mycobacterium%20abscessus%20Subspecies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Feriel%22%2C%22lastName%22%3A%22Bouziane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flora%22%2C%22lastName%22%3A%22Crockett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachid%22%2C%22lastName%22%3A%22Nessar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Chau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Sapriel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Raskine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22Mycobacterium%20abscessus%20is%20an%20emerging%20pathogen%20against%20which%20clarithromycin%20is%20the%20main%20drug%20used.%20Clinical%20failures%20are%20commonly%20observed%20and%20were%20first%20attributed%20to%20acquired%20mutations%20in%20rrl%20encoding%2023S%20rRNA%20but%20were%20then%20attributed%20to%20the%20intrinsic%20production%20of%20the%20erm%2841%29%2023S%20RNA%20methylase.%20Since%20strains%20of%20M.%20abscessus%20were%20recently%20distributed%20into%20subspecies%20and%20erm%2841%29%20sequevars%2C%20we%20investigated%20acquired%20clarithromycin%20resistance%20mechanisms%20in%20mutants%20selected%20in%20vitro%20from%20four%20representative%20strains.%20Mutants%20were%20sequenced%20for%20rrl%2C%20erm%2841%29%2C%20whiB%2C%20rpIV%2C%20and%20rplD%20and%20studied%20for%20seven%20antibiotic%20MICs.%20For%20mutants%20obtained%20from%20strain%20M.%20abscessus%20subsp.%20abscessus%20erm%2841%29%20T28%20sequevar%20and%20strain%20M.%20abscessus%20subsp.%20bolletii%2C%20which%20are%20both%20known%20to%20produce%20effective%20methylase%2C%20rrl%20was%20mutated%20in%20only%2019%25%20%284%5C%2F21%29%20and%2032.5%25%20%2813%5C%2F40%29%20of%20mutants%2C%20respectively%2C%20at%20position%202058%20%28A2058C%2C%20A2058G%29%20or%20position%202059%20%28A2059C%2C%20A2059G%29.%20No%20mutations%20were%20observed%20in%20any%20of%20the%20other%20genes%20studied%2C%20and%20resistance%20to%20other%20antibiotics%20%28amikacin%2C%20cefoxitin%2C%20imipenem%2C%20tigecycline%2C%20linezolid%2C%20and%20ciprofloxacin%29%20was%20mainly%20unchanged.%20For%20M.%20abscessus%20subsp.%20abscessus%20erm%2841%29%20C28%20sequevar%20and%20M.%20abscessus%20subsp.%20massiliense%2C%20not%20producing%20effective%20methylase%2C%20100%25%20%2826%5C%2F26%29%20and%2097.5%25%20%2839%5C%2F40%29%20of%20mutants%20had%20rrl%20mutations%20at%20position%202058%20%28A2058C%2C%20A2058G%2C%20A2058T%29%20or%20position%202059%20%28A2059C%2C%20A2059G%29.%20The%20remaining%20M.%20abscessus%20subsp.%20massiliense%20mutant%20showed%20an%2018-bp%20repeat%20insertion%20in%20rpIV%2C%20encoding%20the%20L22%20protein.%20Our%20results%20showed%20that%20acquisition%20of%20clarithromycin%20resistance%20is%20100%25%20mediated%20by%20structural%2050S%20ribosomal%20subunit%20mutations%20for%20M.%20abscessus%20subsp.%20abscessus%20erm%2841%29%20C28%20and%20M.%20abscessus%20subsp.%20massiliense%2C%20whereas%20it%20is%20less%20common%20for%20M.%20abscessus%20subsp.%20abscessus%20erm%2841%29%20T28%20sequevar%20and%20M.%20abscessus%20subsp.%20bolletii%2C%20where%20other%20mechanisms%20may%20be%20responsible%20for%20failure.%22%2C%22date%22%3A%2201%5C%2F01%5C%2F2017%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.00943-16%22%2C%22ISSN%22%3A%220066-4804%2C%201098-6596%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Faac.asm.org%5C%2Fcontent%5C%2F61%5C%2F1%5C%2Fe00943-16%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-02T14%3A40%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22VAMXEBFX%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sch%5Cu00f6n%20et%20al.%22%2C%22parsedDate%22%3A%222017-03-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESch%26%23xF6%3Bn%2C%20T.%2C%20Miotto%2C%20P.%2C%20K%26%23xF6%3Bser%2C%20C.%20U.%2C%20Viveiros%2C%20M.%2C%20B%26%23xF6%3Bttger%2C%20E.%20and%20Cambau%2C%20E.%20%282017%29.%20%3Cb%3EMycobacterium%20tuberculosis%20drug-resistance%20testing%3A%20challenges%2C%20recent%20developments%20and%20perspectives%3C%5C%2Fb%3E.%20Clinical%20Microbiology%20and%20Infection%20%3Ci%3E23%3C%5C%2Fi%3E%2C%20154%26%23x2013%3B160%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2016.10.022%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2016.10.022%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mycobacterium%20tuberculosis%20drug-resistance%20testing%3A%20challenges%2C%20recent%20developments%20and%20perspectives%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Sch%5Cu00f6n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Miotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20U.%22%2C%22lastName%22%3A%22K%5Cu00f6ser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Viveiros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22B%5Cu00f6ttger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-03-01%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2016.10.022%22%2C%22ISSN%22%3A%221198-743X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.clinicalmicrobiologyandinfection.com%5C%2Farticle%5C%2FS1198-743X%2816%2930511-0%5C%2Ffulltext%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-12T09%3A40%3A18Z%22%7D%7D%2C%7B%22key%22%3A%226BQLWEQA%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Veziris%20et%20al.%22%2C%22parsedDate%22%3A%222017-03-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EVeziris%2C%20N.%2C%20Bernard%2C%20C.%2C%20Guglielmetti%2C%20L.%2C%20Du%2C%20D.%20L.%2C%20Marigot-Outtandy%2C%20D.%2C%20Jaspard%2C%20M.%2C%20Caumes%2C%20E.%2C%20Lerat%2C%20I.%2C%20Rioux%2C%20C.%2C%20Yazdanpanah%2C%20Y.%2C%20Tiotiu%2C%20A.%2C%20Lemaitre%2C%20N.%2C%20Brossier%2C%20F.%2C%20Jarlier%2C%20V.%2C%20Robert%2C%20J.%2C%20Sougakoff%2C%20W.%20and%20Aubry%2C%20A.%20%282017%29.%20%3Cb%3ERapid%20emergence%20of%20Mycobacterium%20tuberculosis%20bedaquiline%20resistance%3A%20lessons%20to%20avoid%20repeating%20past%20errors%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E49%3C%5C%2Fi%3E%2C%201601719%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.01719-2016%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.01719-2016%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rapid%20emergence%20of%20Mycobacterium%20tuberculosis%20bedaquiline%20resistance%3A%20lessons%20to%20avoid%20repeating%20past%20errors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%20Le%22%2C%22lastName%22%3A%22Du%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhiba%22%2C%22lastName%22%3A%22Marigot-Outtandy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Jaspard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Lerat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Rioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yazdan%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angelica%22%2C%22lastName%22%3A%22Tiotiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Lemaitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%5D%2C%22abstractNote%22%3A%22Extract%5CnBedaquiline%20%28BDQ%29%20has%20demonstrated%20potent%20clinical%20activity%20against%20multidrug-resistant%20%28MDR%29%20and%20extensively%20drug-resistant%20%28XDR%29%20Mycobacterium%20tuberculosis%20complex%20strains%20%5B1%5Cu20133%5D.%20It%20has%20now%20been%20used%20in%20%3E50%20countries%2C%20and%20it%20is%20estimated%20that%20%5Cu223c2500%20patients%20had%20been%20treated%20with%20BDQ%20by%20the%20end%20of%202015.%20In%20spite%20of%20its%20recent%20clinical%20use%2C%20there%20are%20few%20reports%20of%20BDQ-resistant%20strains%20%5B4%2C%205%5D.%20Mutations%20in%20the%20rv0678%20gene%20encoding%20the%20MmpL5%20efflux%20pump%20repressor%20generate%20low-level%20BDQ%20resistance%20and%20clofazimine%20%28CFZ%29%20cross-resistance%20%5B6%5D.%20To%20our%20knowledge%2C%20this%20is%20the%20sole%20mechanism%20of%20BDQ%20resistance%20described%20in%20clinical%20strains%20%5B4%2C%205%5D.%20Despite%20its%20introduction%20in%20France%20in%202011%20for%20XDR-%20and%20MDR-tuberculosis%20%28TB%29%20treatment%2C%20we%20report%20herein%20four%20BDQ-resistant%20cases%2C%20and%20discuss%20strategies%20to%20avoid%20a%20surge%20of%20BDQ%20resistance.%5CnBedaquiline%20resistance%20appears%20rapidly%20both%20after%20treatment%20and%20in%20patients%20that%20have%20never%20been%20treated%20http%3A%5C%2F%5C%2Fow.ly%5C%2FmxEM30604OF%22%2C%22date%22%3A%222017%5C%2F03%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.01719-2016%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F49%5C%2F3%5C%2F1601719%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-02T14%3A46%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22WGRZSFI6%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wyplosz%20et%20al.%22%2C%22parsedDate%22%3A%222017-02-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EWyplosz%2C%20B.%2C%20Mougari%2C%20F.%2C%20Rawi%2C%20M.%20A.%2C%20Baillon%2C%20C.%2C%20Marigot-Outtandy%2C%20D.%2C%20D%26%23xFB%3B%2C%20D.%20L.%2C%20Jachym%2C%20M.%2C%20Herv%26%23xE9%3B%2C%20V.%2C%20Raskine%2C%20L.%20and%20Cambau%2C%20E.%20%282017%29.%20%3Cb%3EVisualizing%20viable%20Mycobacterium%20tuberculosis%20in%20sputum%20to%20monitor%20isolation%20measures%3C%5C%2Fb%3E.%20Journal%20of%20Infection%20%3Ci%3E74%3C%5C%2Fi%3E%2C%20207%26%23x2013%3B210%2C%20%3Ca%20class%3D%27zp-DOIURL%27%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2016.11.014%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2016.11.014%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Visualizing%20viable%20Mycobacterium%20tuberculosis%20in%20sputum%20to%20monitor%20isolation%20measures%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Wyplosz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22May%20Al%22%2C%22lastName%22%3A%22Rawi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Baillon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhiba%22%2C%22lastName%22%3A%22Marigot-Outtandy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%20Le%22%2C%22lastName%22%3A%22D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Herv%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Raskine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22In%20this%20Journal%2C%20Awoniyi%20and%20colleagues%20evaluated%20cytokine%20responses%20against%20novel%5CnMtb%20antigens%20as%20diagnostic%20markers%20for%20TB%20disease.%20However%20a%20practical%20issue%20for%20physicians%5Cnlooking%20after%20patients%20with%20TB%20is%20being%20able%20to%20distinguish%20smear%20positive%5C%2Fculture%5Cnnegative%20patients%20during%20the%20early%20phases%20of%20treatment.1%20Isolation%20measures%20are%20mandatory%5Cnfor%20patients%20hospitalized%20with%20pulmonary%20tuberculosis%20%28TB%29%2C%20in%20order%20to%20prevent%20transmission.2%5CnAlthough%20the%20average%20time%20to%20culture%20conversion%20is%20one%20month%20for%20patients%20with%20drug-susceptible%5CnTB%2C3%205%25%5Cu201330%25%20cases%20require%20more%20than%20two%20months4%20and%20up%20to%206%20months%20can%20be%20required%5Cnfor%20MDR-TB.%22%2C%22date%22%3A%222017%5C%2F02%5C%2F01%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jinf.2016.11.014%22%2C%22ISSN%22%3A%220163-4453%2C%201532-2742%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.journalofinfection.com%5C%2Farticle%5C%2FS0163-4453%2816%2930313-9%5C%2Fabstract%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222019-04-03T22%3A22%3A22Z%22%7D%7D%5D%7D
Allerberger, F., Cambau, E. and Lange, C. (2017). Joint efforts urgently needed at times of emerging tuberculosis drug resistance. Clinical Microbiology and Infection 23, 129–130, http://doi.org/10.1016/j.cmi.2016.08.023.
Andre, E., Goeminne, L., Cabibbe, A., Beckert, P., Mukadi, B. K., Mathys, V., Gagneux, S., Niemann, S., Ingen, J. V. and Cambau, E. (2017). Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clinical Microbiology and Infection 23, 167–172, http://doi.org/10.1016/j.cmi.2016.09.006.
Appelgren, A., Morquin, D., Dufour, S., Le Moing, V., Reynes, J., Lotthé, A., Parer, S., Corbeau, C., Aubry, A., Sougakoff, W., Solassol, J., Bonzon, L., Dumont, Y. and Godreuil, S. (2017). Investigation of pre-XDR Beijing Mycobacterium tuberculosis transmission to a healthcare worker in France, 2016. Journal of Hospital Infection, http://doi.org/10.1016/j.jhin.2017.06.030.
Aubry, A., Mougari, F., Reibel, F. and Cambau, E. (2017). Mycobacterium marinum. Microbiology Spectrum 5, http://doi.org/10.1128/microbiolspec.TNMI7-0038-2016.
Bouchet, F., Martin, B., Aubry, A., Veziris, N., Lavigne, J.-P. and Sotto, A. (2017). Should single antibiotic therapy be avoided for nontuberculous mycobacteria? Médecine et Maladies Infectieuses, http://doi.org/10.1016/j.medmal.2017.07.004.
Brossier, F. and Sougakoff, W. (2017). Molecular detection methods of resistance to antituberculosis drugs in Mycobacterium tuberculosis. Médecine et Maladies Infectieuses 47, 340–348, http://doi.org/10.1016/j.medmal.2017.04.008.
Brossier, F., Pham, A., Bernard, C., Aubry, A., Jarlier, V., Veziris, N., Sougakoff, W. and CNR-MyRMA, O. B. of T. (2017). Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France. Antimicrob Agents Chemother 61, e01299-16, http://doi.org/10.1128/AAC.01299-16.
Delafont, V., Samba-Louaka, A., Cambau, E., Bouchon, D., Moulin, L. and Héchard, Y. (2017). Mycobacterium llatzerense, a waterborne Mycobacterium, that resists phagocytosis by Acanthamoeba castellanii. Scientific Reports 7, 46270, http://doi.org/10.1038/srep46270.
Fournier, A., Bernard, C., Sougakoff, W., Quelet, S., Antoun, F., Charlois-Ou, C., Dormant, I., Dufour, M.-O., Hocine, N., Jarlier, V. and Veziris, N. (2017). Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission. European Respiratory Journal 50, 1700891, http://doi.org/10.1183/13993003.00891-2017.
Guglielmetti, L., Jaspard, M., Dû, D. L., Lachâtre, M., Marigot-Outtandy, D., Bernard, C., Veziris, N., Robert, J., Yazdanpanah, Y., Caumes, E. and Fréchet-Jachym, M. (2017). Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. European Respiratory Journal 49, 1601799, http://doi.org/10.1183/13993003.01799-2016.
Guglielmetti, L., Hewison, C., Avaliani, Z., Hughes, J., Kiria, N., Lomtadze, N., Ndjeka, N., Setkina, S., Shabangu, A., Sikhondze, W., Skrahina, A., Veziris, N. and Furin, J. (2017). Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. The International Journal of Tuberculosis and Lung Disease 21, 167–174, http://doi.org/10.5588/ijtld.16.0493.
Jaspard, M., Elefant-Amoura, E., Melonio, I., de Montgolfier, I., Veziris, N. and Caumes, E. (2017). Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman. Emerging Infect Dis 23, http://doi.org/10.3201/eid2310.161398.
Leyer, C., Gregorowicz, G., Mougari, F., Raskine, L., Cambau, E. and Briel, D. de (2017). Comparison of Saramis 4.12 and IVD 3.0 Vitek MS Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry for Identification of Mycobacteria from Solid and Liquid Culture Media. Journal of Clinical Microbiology 55, 2045–2054, http://doi.org/10.1128/JCM.00006-17.
Maitre, T., Aubry, A. and Veziris, N. (2017). Molecular Drug-Susceptibility Test for Tuberculosis. New England Journal of Medicine 377, 2403–2404, http://doi.org/10.1056/NEJMc1714218.
Maitre, T., Petitjean, G., Chauffour, A., Bernard, C., El Helali, N., Jarlier, V., Reibel, F., Chavanet, P., Aubry, A. and Veziris, N. (2017). Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis? J Antimicrob Chemother 72, 2326–2333, http://doi.org/10.1093/jac/dkx150.
Maitre, T., Aubry, A., Jarlier, V., Robert, J., Veziris, N., Bernard, C., Sougakoff, W., Brossier, F., Cambau, E., Mougari, F. and Raskine, L. (2017). Multidrug and extensively drug-resistant tuberculosis. Médecine et Maladies Infectieuses 47, 3–10, http://doi.org/10.1016/j.medmal.2016.07.006.
Mazoyer, A., Ycart, B. and Veziris, N. (2017). Correction: Unbiased Estimation of Mutation Rates under Fluctuating Final Counts. PLOS ONE 12, e0173143, http://doi.org/10.1371/journal.pone.0173143.
Mougari, F., Loiseau, J., Veziris, N., Bernard, C., Bercot, B., Sougakoff, W., Jarlier, V., Raskine, L. and Cambau, E. (2017). Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. J Antimicrob Chemother 72, 1669–1677, http://doi.org/10.1093/jac/dkx021.
Mougari, F., Bouziane, F., Crockett, F., Nessar, R., Chau, F., Veziris, N., Sapriel, G., Raskine, L. and Cambau, E. (2017). Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. Antimicrob Agents Chemother 61, e00943-16, http://doi.org/10.1128/AAC.00943-16.
Schön, T., Miotto, P., Köser, C. U., Viveiros, M., Böttger, E. and Cambau, E. (2017). Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. Clinical Microbiology and Infection 23, 154–160, http://doi.org/10.1016/j.cmi.2016.10.022.
Veziris, N., Bernard, C., Guglielmetti, L., Du, D. L., Marigot-Outtandy, D., Jaspard, M., Caumes, E., Lerat, I., Rioux, C., Yazdanpanah, Y., Tiotiu, A., Lemaitre, N., Brossier, F., Jarlier, V., Robert, J., Sougakoff, W. and Aubry, A. (2017). Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. European Respiratory Journal 49, 1601719, http://doi.org/10.1183/13993003.01719-2016.
Wyplosz, B., Mougari, F., Rawi, M. A., Baillon, C., Marigot-Outtandy, D., Dû, D. L., Jachym, M., Hervé, V., Raskine, L. and Cambau, E. (2017). Visualizing viable Mycobacterium tuberculosis in sputum to monitor isolation measures. Journal of Infection 74, 207–210, http://doi.org/10.1016/j.jinf.2016.11.014.